Fotemustine (S 10036) in the Intra-Arterial Treatment of Liver Metastasis from Malignant Melanoma

Autor: J. P. Bizzari, G. Cohen-Alloro, J. C. Bousquet, K. Aigner, B. Audhuy, Cecil O. Borel, D. Buthiau, David Khayat, Jacquillat C, M. Weil, Gérard Auclerc, V. Cour

Publikováno v: American Journal of Clinical Oncology. 14:400-404

Fotemustine is a new nitrosourea which has shown some efficacy on disseminated malignant melanoma (DMM) (24.2% response rate (RR) among 153 patients in a Phase II trial) but little activity on hepatic metastasis (8.8% RR). In order to improve those p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43627cd6daf5a406f8b264a338b5c1c
https://doi.org/10.1097/00000421-199110000-00008

Cytostatic Anticancer Drug Development: Preclinical Studies and Early Clinical Trials

Autor: H. Ludwig, K. Havemann, K. Pollow, B. Kornhuber, G. Maschmeyer, M.E. Heim, H. Deicher, W. Hiddemann, H. Wilke, L. Hoffmann, F. Overkamp, K. Lennert, R. Waldmann, M.v. Bülow, H. Gisslinger, H. Köppler, W. Bätz, H. Stein, A. Grothey, E. Fritz, U. Cammerer, M. Fritz, H. Flechtner, J. Stirbu, S. Kunz, D.K. Hossfeld, L. Edler, G.v. Ingersleben, D. Schmähl, C. Gropp, S. Verhees, W. Queißer, M.R. Berger, E. Busse, R. Herrmann, J. Selbach, P. Drings, S. Oehl, H. Konyar, U. Bruntsch, D. Hossfeld, I.-M. v. Broen, R. Holle, V. Cour, H. Link, D. Adam, F. Trux, A. Sinop, H. Kuhn, W. Zeller, E.U. Steinhauer, E. Neeser, B. Steinke, P. Unterburger, K. Schumacher, J.P. Obrecht, B. Mentges, P. Preusser, H. Langenbahn, R. Coldewey, M. Fink, A. Ganser, E. Lötzke, J. Hartlapp, R. Pfab, K. Höffken, M. Flasshove, M. Helmerking, H. J. Schmoll, D. Peest, W. Noder, H. Kotzmann, D. Hoelzer, H.O. Klein, E.D. Kreuser, H.H. Goßmann, H.J. Weh, H.-J. Grill, H. Ehrhart, R. Hein, K.H. Pflüger, C.N. Gutt, E. Heidemann, I. Eschenbach, K. Possinger, P. Meyer

Publikováno v: Oncology Research and Treatment. 13:57-60

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a3331db1962955371764c52860abd3c
https://doi.org/10.1159/000216722

Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine

Autor: V. Oliver, V. Cour, Eliana Pérez, A. Ponchon, J.P. Bizzari, A. Aliaga, JJ Lopez Lopez

Publikováno v: European journal of cancer (Oxford, England : 1990). (2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3af7cf5eb20f1997ecd08c37b020cd0
https://pubmed.ncbi.nlm.nih.gov/8422299

Hepatic intra-arterial infusion of fotemustine: pharmacokinetics

Autor: P. Solere, V. Cour, J. Vignoud, R. Fety, C. Lucas

Publikováno v: Cancer chemotherapy and pharmacology. 31(2)

Fotemustine is a new nitrosourea derivative that contains an alpha-aminophosphonic acid and has a short half-life and a high plasma clearance. As myelosuppression occurs as the dose-limiting toxicity, local drug delivery has been investigated in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b4abcd148e507c8533c7b1f7f1f4f2
https://pubmed.ncbi.nlm.nih.gov/1451232

[Fotemustine, a new nitrosourea derivative. Current status of development]

Autor: V, Cour, H, Langenbahn

Publikováno v: Onkologie. 13(1)

Fotemustine is a new chloronitrosourea recently developed by the French company Servier. It is chemically characterized by the graft of an aminophosphonic acid on the chloronitrosourea radical, which makes it highly lipophil. The preclinical studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8af7ee31d00748911115d8af1158d561
https://pubmed.ncbi.nlm.nih.gov/2186326